Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years

Manolo Piccirilli, Simona Bistazzoni, Franco Maria Gagliardi, Alessandro Landi, Antonio Santoro, Felice Giangaspero, Maurizio Salvati

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We report our remarks on 22 patients, 80 years of age and older, who were treated for glioblastoma multiforme. The 16 patients who underwent a multimodality treatment (surgery + radiotherapy + chemotherapy) had an average survival of 16.7 months versus the 5.8 months of the 8 patients treated with biopsy followed by radiotherapy and/or chemotherapy (log-rank test, P <0.001). Moreover, we point out the importance of MGMT hypermethylation as a significant prognostic factor: the 9 patients with nonmethylated MGMT had a mean survival of 7.7 months vs 17.9 months of the 13 patients with the MGMT promoter methylated (log-rank test. P = 0.0006). Several studies have pointed out age as an important negative factor for the outcome of elderly patients affected by glioblastoma multiforme. Elderly patients with a diagnosis of glioblastoma multiforme are thus generally excluded from clinical trials of treatment for the neoplasm, because it is a common opinion that the prognosis for such patients is particularly poor. On the contrary, according to our clinical and surgical experience, we firmly believe that patients older than 80 years with a histologically proven diagnosis of glioblastoma multiforme and in good health conditions (Karnofsky performance status >60) should be treated in the same way as younger patients.

Original languageEnglish
Pages (from-to)98-103
Number of pages6
JournalTumori
Volume92
Issue number2
Publication statusPublished - Mar 2006

Fingerprint

Glioblastoma
Radiotherapy
Drug Therapy
Therapeutics
Biopsy
Survival

Keywords

  • Chemotherapy
  • Elderly cancer patients
  • Glioblastoma multiforme
  • Long-term follow-up
  • Multimodality treatment
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Cancer Research

Cite this

Piccirilli, M., Bistazzoni, S., Gagliardi, F. M., Landi, A., Santoro, A., Giangaspero, F., & Salvati, M. (2006). Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori, 92(2), 98-103.

Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. / Piccirilli, Manolo; Bistazzoni, Simona; Gagliardi, Franco Maria; Landi, Alessandro; Santoro, Antonio; Giangaspero, Felice; Salvati, Maurizio.

In: Tumori, Vol. 92, No. 2, 03.2006, p. 98-103.

Research output: Contribution to journalArticle

Piccirilli, M, Bistazzoni, S, Gagliardi, FM, Landi, A, Santoro, A, Giangaspero, F & Salvati, M 2006, 'Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years', Tumori, vol. 92, no. 2, pp. 98-103.
Piccirilli M, Bistazzoni S, Gagliardi FM, Landi A, Santoro A, Giangaspero F et al. Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori. 2006 Mar;92(2):98-103.
Piccirilli, Manolo ; Bistazzoni, Simona ; Gagliardi, Franco Maria ; Landi, Alessandro ; Santoro, Antonio ; Giangaspero, Felice ; Salvati, Maurizio. / Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. In: Tumori. 2006 ; Vol. 92, No. 2. pp. 98-103.
@article{73dcc6fd060b4fb688d1639fdd4dc82f,
title = "Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years",
abstract = "We report our remarks on 22 patients, 80 years of age and older, who were treated for glioblastoma multiforme. The 16 patients who underwent a multimodality treatment (surgery + radiotherapy + chemotherapy) had an average survival of 16.7 months versus the 5.8 months of the 8 patients treated with biopsy followed by radiotherapy and/or chemotherapy (log-rank test, P <0.001). Moreover, we point out the importance of MGMT hypermethylation as a significant prognostic factor: the 9 patients with nonmethylated MGMT had a mean survival of 7.7 months vs 17.9 months of the 13 patients with the MGMT promoter methylated (log-rank test. P = 0.0006). Several studies have pointed out age as an important negative factor for the outcome of elderly patients affected by glioblastoma multiforme. Elderly patients with a diagnosis of glioblastoma multiforme are thus generally excluded from clinical trials of treatment for the neoplasm, because it is a common opinion that the prognosis for such patients is particularly poor. On the contrary, according to our clinical and surgical experience, we firmly believe that patients older than 80 years with a histologically proven diagnosis of glioblastoma multiforme and in good health conditions (Karnofsky performance status >60) should be treated in the same way as younger patients.",
keywords = "Chemotherapy, Elderly cancer patients, Glioblastoma multiforme, Long-term follow-up, Multimodality treatment, Radiotherapy, Surgery",
author = "Manolo Piccirilli and Simona Bistazzoni and Gagliardi, {Franco Maria} and Alessandro Landi and Antonio Santoro and Felice Giangaspero and Maurizio Salvati",
year = "2006",
month = "3",
language = "English",
volume = "92",
pages = "98--103",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years

AU - Piccirilli, Manolo

AU - Bistazzoni, Simona

AU - Gagliardi, Franco Maria

AU - Landi, Alessandro

AU - Santoro, Antonio

AU - Giangaspero, Felice

AU - Salvati, Maurizio

PY - 2006/3

Y1 - 2006/3

N2 - We report our remarks on 22 patients, 80 years of age and older, who were treated for glioblastoma multiforme. The 16 patients who underwent a multimodality treatment (surgery + radiotherapy + chemotherapy) had an average survival of 16.7 months versus the 5.8 months of the 8 patients treated with biopsy followed by radiotherapy and/or chemotherapy (log-rank test, P <0.001). Moreover, we point out the importance of MGMT hypermethylation as a significant prognostic factor: the 9 patients with nonmethylated MGMT had a mean survival of 7.7 months vs 17.9 months of the 13 patients with the MGMT promoter methylated (log-rank test. P = 0.0006). Several studies have pointed out age as an important negative factor for the outcome of elderly patients affected by glioblastoma multiforme. Elderly patients with a diagnosis of glioblastoma multiforme are thus generally excluded from clinical trials of treatment for the neoplasm, because it is a common opinion that the prognosis for such patients is particularly poor. On the contrary, according to our clinical and surgical experience, we firmly believe that patients older than 80 years with a histologically proven diagnosis of glioblastoma multiforme and in good health conditions (Karnofsky performance status >60) should be treated in the same way as younger patients.

AB - We report our remarks on 22 patients, 80 years of age and older, who were treated for glioblastoma multiforme. The 16 patients who underwent a multimodality treatment (surgery + radiotherapy + chemotherapy) had an average survival of 16.7 months versus the 5.8 months of the 8 patients treated with biopsy followed by radiotherapy and/or chemotherapy (log-rank test, P <0.001). Moreover, we point out the importance of MGMT hypermethylation as a significant prognostic factor: the 9 patients with nonmethylated MGMT had a mean survival of 7.7 months vs 17.9 months of the 13 patients with the MGMT promoter methylated (log-rank test. P = 0.0006). Several studies have pointed out age as an important negative factor for the outcome of elderly patients affected by glioblastoma multiforme. Elderly patients with a diagnosis of glioblastoma multiforme are thus generally excluded from clinical trials of treatment for the neoplasm, because it is a common opinion that the prognosis for such patients is particularly poor. On the contrary, according to our clinical and surgical experience, we firmly believe that patients older than 80 years with a histologically proven diagnosis of glioblastoma multiforme and in good health conditions (Karnofsky performance status >60) should be treated in the same way as younger patients.

KW - Chemotherapy

KW - Elderly cancer patients

KW - Glioblastoma multiforme

KW - Long-term follow-up

KW - Multimodality treatment

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=33744756283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744756283&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 98

EP - 103

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -